• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

双联联合疗法与长效支气管扩张剂单药治疗慢性阻塞性肺疾病（COPD）的疗效比较：一项系统评价与网状Meta分析

Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis.

作者信息

Oba Yuji, Pathak Mona, Maduke Tinashe, Fakhouri Eddie W, Dias Sofia

机构信息

Division of Pulmonary and Critical Care Medicine, University of Missouri, Columbia, MO, USA.

Pharmacotherapy College of Pharmacy, University of North Texas Health Science Center, Flower Mound, Texas, USA.

出版信息

Cochrane Database Syst Rev. 2025 Apr 3;4(4):CD015997. doi: 10.1002/14651858.CD015997.

DOI:10.1002/14651858.CD015997
PMID:40178181
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11967328/
Abstract

This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the comparative efficacy and safety of fixed-dose dual inhalers (i.e. LABA/LAMA versus ICS/LABA) and combination therapies versus LABA or LAMA monotherapy in individuals with moderate to very severe COPD, using network meta-analysis, and to rank these treatments based on their efficacy and safety.

摘要

这是一项Cochrane系统评价（干预措施）的方案。目标如下：采用网状Meta分析评估中重度至极重度慢性阻塞性肺疾病（COPD）患者使用固定剂量双吸入器（即长效β2受体激动剂/长效抗胆碱能药物与吸入性糖皮质激素/长效β2受体激动剂）以及联合疗法与长效β2受体激动剂或长效抗胆碱能药物单药治疗相比的疗效和安全性，并根据疗效和安全性对这些治疗方法进行排序。

相似文献

1
Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis.双联联合疗法与长效支气管扩张剂单药治疗慢性阻塞性肺疾病（COPD）的疗效比较：一项系统评价与网状Meta分析
Cochrane Database Syst Rev. 2025 Apr 3;4(4):CD015997. doi: 10.1002/14651858.CD015997.
2
Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis.慢性阻塞性肺疾病的长效吸入疗法（β受体激动剂、抗胆碱能药物和类固醇）：一项网状荟萃分析。
Cochrane Database Syst Rev. 2014 Mar 26;2014(3):CD010844. doi: 10.1002/14651858.CD010844.pub2.
3
Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β-Agonist (ICS/LAMA/LABA) Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis.布地奈德/格隆溴铵/富马酸福莫特罗干粉吸入剂（BGF MDI）对比其他吸入性皮质类固醇/长效毒蕈碱拮抗剂/长效β激动剂（ICS/LAMA/LABA）三联复方制剂治疗 COPD 的疗效：系统文献评价和网络荟萃分析。
Adv Ther. 2020 Jun;37(6):2956-2975. doi: 10.1007/s12325-020-01311-3. Epub 2020 Apr 25.
4
Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis.乌美溴铵/维兰特罗与其他支气管扩张剂治疗慢性阻塞性肺疾病的疗效比较：一项网络荟萃分析。
Adv Ther. 2022 Nov;39(11):4961-5010. doi: 10.1007/s12325-022-02234-x. Epub 2022 Jul 20.
5
LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis.长效β2受体激动剂/长效毒蕈碱受体拮抗剂联合治疗与长效毒蕈碱受体拮抗剂单药治疗或长效β2受体激动剂/吸入性糖皮质激素治疗慢性阻塞性肺疾病的系统评价和荟萃分析
Int J Chron Obstruct Pulmon Dis. 2017 Mar 17;12:907-922. doi: 10.2147/COPD.S130482. eCollection 2017.
6
Once-daily long-acting beta₂-agonists/inhaled corticosteroids combined inhalers versus inhaled long-acting muscarinic antagonists for people with chronic obstructive pulmonary disease.对于慢性阻塞性肺疾病患者，每日一次长效β₂受体激动剂/吸入性糖皮质激素联合吸入器与吸入性长效毒蕈碱拮抗剂的比较
Cochrane Database Syst Rev. 2018 Aug 24;8(8):CD012355. doi: 10.1002/14651858.CD012355.pub2.
7
Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease.吸入性皮质类固醇联合吸入长效β2-激动剂和长效抗胆碱能药物治疗慢性阻塞性肺疾病。
Cochrane Database Syst Rev. 2023 Dec 6;12(12):CD011600. doi: 10.1002/14651858.CD011600.pub3.
8
Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD).长效毒蕈碱拮抗剂（LAMA）联合长效β受体激动剂（LABA）与LABA联合吸入性糖皮质激素（ICS）用于稳定期慢性阻塞性肺疾病（COPD）的比较
Cochrane Database Syst Rev. 2017 Feb 10;2(2):CD012066. doi: 10.1002/14651858.CD012066.pub2.
9
Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease.吸入性糖皮质激素与慢性阻塞性肺疾病患者的肺炎风险
Cochrane Database Syst Rev. 2014 Mar 10;2014(3):CD010115. doi: 10.1002/14651858.CD010115.pub2.
10
Inhaled corticosteroids with combination inhaled long-acting beta-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease.吸入性糖皮质激素与吸入性长效β受体激动剂及长效毒蕈碱拮抗剂联合用于慢性阻塞性肺疾病
Cochrane Database Syst Rev. 2016 Nov 10;11(11):CD011600. doi: 10.1002/14651858.CD011600.pub2.

本文引用的文献

1
Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease.长效毒蕈碱拮抗剂（LAMA）联合长效β-激动剂（LABA）与 LABA 联合吸入皮质类固醇（ICS）治疗稳定期慢性阻塞性肺疾病。
Cochrane Database Syst Rev. 2023 Jun 5;6(6):CD012066. doi: 10.1002/14651858.CD012066.pub3.
2
Chronic Obstructive Pulmonary Disease Exacerbations and Pneumonia Hospitalizations Among New Users of Combination Maintenance Inhalers.慢性阻塞性肺疾病加重和新使用联合维持吸入器患者的肺炎住院。
JAMA Intern Med. 2023 Jul 1;183(7):685-695. doi: 10.1001/jamainternmed.2023.1245.
3
Data Collection Issues With Mortality Risk of Inhaled Corticosteroids in COPD.慢性阻塞性肺疾病中吸入性糖皮质激素死亡率风险的数据收集问题
Chest. 2023 May;163(5):e247. doi: 10.1016/j.chest.2023.01.040.
4
GRADE guidance 36: updates to GRADE's approach to addressing inconsistency.GRADE 指南 36：更新 GRADE 解决不一致性的方法。
J Clin Epidemiol. 2023 Jun;158:70-83. doi: 10.1016/j.jclinepi.2023.03.003. Epub 2023 Mar 9.
5
Association of Inhaled Corticosteroids With All-Cause Mortality Risk in Patients With COPD: A Meta-analysis of 60 Randomized Controlled Trials.吸入皮质类固醇与 COPD 患者全因死亡率的相关性：60 项随机对照试验的荟萃分析。
Chest. 2023 Jan;163(1):100-114. doi: 10.1016/j.chest.2022.07.015. Epub 2022 Jul 31.
6
Burden of chronic obstructive pulmonary disease and its attributable risk factors in 204 countries and territories, 1990-2019: results from the Global Burden of Disease Study 2019.204 个国家和地区 1990-2019 年慢性阻塞性肺疾病负担及其可归因危险因素：2019 年全球疾病负担研究结果。
BMJ. 2022 Jul 27;378:e069679. doi: 10.1136/bmj-2021-069679.
7
An Updated Definition and Severity Classification of Chronic Obstructive Pulmonary Disease Exacerbations: The Rome Proposal.慢性阻塞性肺疾病急性加重的更新定义与严重程度分类：罗马提议
Am J Respir Crit Care Med. 2021 Dec 1;204(11):1251-1258. doi: 10.1164/rccm.202108-1819PP.
8
Prevalence and Population-Attributable Risk for Chronic Airflow Obstruction in a Large Multinational Study.在一项大型跨国研究中慢性气流阻塞的流行率和人群归因危险度。
Am J Respir Crit Care Med. 2021 Jun 1;203(11):1353-1365. doi: 10.1164/rccm.202005-1990OC.
9
Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD.中重度至极重度 COPD 患者两种糖皮质激素剂量三联吸入治疗。
N Engl J Med. 2020 Jul 2;383(1):35-48. doi: 10.1056/NEJMoa1916046. Epub 2020 Jun 24.
10
Acute exacerbations of chronic obstructive pulmonary disease: in search of diagnostic biomarkers and treatable traits.慢性阻塞性肺疾病急性加重：寻找诊断生物标志物和可治疗特征。
Thorax. 2020 Jun;75(6):520-527. doi: 10.1136/thoraxjnl-2019-214484. Epub 2020 Mar 26.